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SHORT COMMUNICATION
Codon 249 mutation of the p53 gene is a rare event in hepatocellular
carcinomas from ethnic Chinese in Singapore
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'Department ofCommuoity, Occupational and Family Medicine, 2Department ofMirobiology, 3Department ofPathology and
4Institute ofMoleculkr and Cell Biology, National University ofSingapore, Kent Ridge Road, Singapore 0511.
Smaqy The present study characterised p53 mutations in 44 hepatocellular carcinomas (HCCs) from
Chinese patients residing in a high-uinence area Twelve point mutations (27%) were detected in tumour
tissues using singern d conformation polymorphism analysis followed by direct DNA sequencing. Remark-
ably, no mutations were observed at codon 249. This is in contrast to HCCs from other high HCC incidence
areas with endemi aflatoxn exposures, which codon 249 a mutational hotspot. It is therefore sugged
that risk factors other than ditary exposure to afiatoxin may contribute to the high HCC incidence in
Singapore.
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Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide (Parlin et al., 1988). The incidence of
HCC, however, varies considerably among different geo-
graphic areas in the world. While HCC is relatively uncom-
mon in North America and Europe, it is rather prevalent in
China, sub-Saharan Africa and South-East Asia (Bosch and
Munoz, 1988; Harris, 1990). Epidemiological studies have
identified chronic hepatitis B virus (HBV) infections and
dietary exposure to aflatoxin B, (AFB,) as major and pos-
sibly synergistic risk factors (Munoz and Bosch, 1987).
Recent studies have implicated the tumour-suppressor gene
p53 as playing a critical role in the development of human
cancers. The p53 gene is known to exhibit disinct mutational
patterns in various cancer types, which may reflect
aetiological contributions of exogenous (environmental) and/
or endogenous factors in the development of human cancers
(Harris and Hollstein, 1993). HCCs have been shown to
display diinct patterns of p53 mutations according to
different geographic locations. In HCCs from patients
residing in areas with low HCC incidence (e.g. Europe and
North America), p53 mutations are scattered and occur in
many different codons of the gene (Kress et al., 1992;
Debuire et al., 1993). However, in HCCs from high-incidence
areas (e.g. China, Africa), where chronic infection with HBV
and dietary exposure to AFBI are known nsk factors, the
predominant mutation types are G:C+T:A base transver-
sions, which also tend to cluster at codon 249 of the gene
(Bressac et al., 1991; Hsu et al., 1991; Ozturk et al., 1991;
Scorsone et al., 1992). This selective hotspot mutation is
found in 30-50% of tumours from high-incidence areas.
Evidence from several studies suggests that such a striking
mutagenic specificity could be attributed to dietary exposure
to AFBI as the same type of mutation could be generated in
in vitro mutagenesis experiments using AFBI (Foster et al.,
1983; Levy et al., 1992; Aguilar et al., 1993). Nevertheless,
aetiological contributions of AEBI and HBV in the develop-
ment of HCC remain unclear since most of the high-
incidence areas are also at a high risk for HBV infections. It
is possible that HBV or the synergistic interaction between
HBV and AFB, could be a prerequisite for the generation of
specific mutations at codon 249. It is thus necessary to
examine p53 mutations in HCC patients exposed either to
high levels of AFB, or to HBV, or neither of the two.
Materials and -bod
Twnour materials andDNA extraction
Forty-four HCC tissue samples were obtained from patients
who had undergone surgical resection. Of these, 38 samples
were formalin fixed and paraffin embedded and six were
freshly frozen. The tumours were graded I-IV on the basis
of decreasing degree of cellular differentiation according to
Edmondson and Steiner's classification. Tumour size as well
as the presence of intravascular invasion were also
documented.
DNA from frozen HCC specimens was extracted according
to the method described by Krieg et al. (1983). Extraction of
DNA from paraffin-embedded tissues followed a previously
described procedure (Radosevich et al., 1991), except that
deparaffinised tissue sections were incubated with SSE buffer
(0.3 M sodium acetate, 0.5% SDS, 5 mM EDTA, pH 8.3),
followed by the standard phenol-chloroform extraction. His-
topathological examination was done on each sample to
ensure that only tumorous tissues were used for DNA extrac-
tion. DNA extracted from the white blood cells of a healthy
subject was always included as a normal control in the
experiments. For genetic analyses, exons 5-8 of the p53
gene, a region which is evolutionarily conserved and is prone
to mutations, were amplified individually by polymerase
chain reactions (PCR), using the primers described in Figure
2.
Detection of mutations in exons 5-8 ofthe p53 gene
Mutations of exons 5-8 of the p53 gene were examind by
single-strand conformation polymorphism (SSCP) analysis
(Orita et al., 1989). DNA fragments that showed abnormal
SSCP bandshifts were subjected to direct sequencing by the
cycle-sequencing method of Craxton (1991) using the same
primers for PCR.
Screening ofcodon 249 mutations by restriction enzyme
analysis
PCR products containing exon 7 of the p53 gene were
digested with the restriction enzyme HaeHI at 3TC for I h.
The digested DNA was then electrophoresed on a 2%
agarose gel. The wild-type sequence contains two HaeIlH
restriction sites. Any point mutations at the second or third
base of codon 249 would result in the abolition of a restric-
tion site, yielding two cut fragments (155 bp, 33 bp) instead
of three (89 bp, 66bp, 33 bp), as seen in the wild-type.
Correspondence: CY 'Shi
Received 2 September 1994; revised 3 February 1995; accepted 7
February 1995p53 _"m in kw cancrs fromSingapore CNnese
CY StI et al
Results
Forty-four hepatocellular carcinomas (HCCs) from Chinese
patients in Singapore, a high-incidence area, were analysed
for p53 mutations. Of these patients, 38 were males and six
were females. Their ages ranged from 30 to 76 years with a
mean of 54 years. Thirty-one patients were tested seropositive
for hepatitis B surface antigen (HBsAg). Liver cirrhosis was
present in 16 patients. Of the 44 tumours examined. 13
(29.5%) showed abnormal SSCP bandshifts (Figure 1), sug-
gesting the presence of mutations in these exons. Subsequent
DNA sequencing confirmed that all 13 cases harboured point
mutations in exons 5-8 (Figure 2). The observed mutations
are summarised in Table I. The point mutations were dist-
ributed throughout exons 5-8. No mutational hotspots were
found. All mutations were single base substitutions and no
other types of sequence alteration, such as insertions or
deletions, were present. All point mutations except two (cases
nos. 10 and 34) resulted in amino acid substitutions. A C+G
transversion in codon 236 of case no. 13 led to a stop codon,
thereby terminating the reading frame. In one case (no. 2), a
double mutation was found at codon 162 and codon 248.
Surprisingly, no mutations were observed at codon 249,
which is believed to be a mutational hotspot in HCCs. This
finding was further confirmed by HaeIlI restriction enzyme
digestion which cuts the wild-type sequence at codon 249.
Figure 3 shows typical HaeIII digestion patterns from
tumour as well as control DNA samples. DNA from all 44
tumour cases were examined by HaeIII digestion. All samples
Figre 1 SSCP analysis of p53 exon 8 amplified by polymerase
chain reaction (PCR). The arrow indicates the bandshift present
in DNA from case no. 34 (lane 1). Lane 4 contains control DNA
from white blood cells of a normal subject. The forward and
reverse primers used for PCR are:
Exon 5 F, 5'-TTCCTCYlfCCTGCAGTACTC-3'
R. 5'-ACCCTGGGCAACCAGCCCTGT-3'
Exon 6 F, 5'-ACAGGGCTGGTTGCCCAGGGT-3'
R, 5'-AGTTGCAAACCAGACCTCAG-3'
Exon 7 F, 5'-GTGTfTATCTCCTAGGTTGGC-3'
R. 5'-GTCAGAGGCAAGCAGAGGCT-3'
Exon 8 F, 5'-TATCCTGAGTAGTGGTAATC-3'
R, 5'-AAGTGAATCTGAGGCATAAC-3'
showed completely cut fragments. corresponding to the wild-
type sequence.
The majority of the subjects (31/44 or 70%) were HBV
carriers, as measured by serum HBsAg. A slightly higher
percentage of HBV carriers was observed among the cases
with p53 mutations (10/13 or 77%). The mutation rate was
similar in tumours with different histological grades (Table
II). However, mutations were more prevalent in tumours
larger than 5cm (33%) than in smaller tumours (17%). All
point mutations occurred in tumours exhibiting intravascular
invasion. Four mutations were found in cirrhotic livers (cases
nos. 5, 10, 13, 14).
Disca
HCC is the third most common cancer among males in
Singapore, with an average age-standardised incidence of 31
per 100 000 persons among Chinese males (Lee et al., 1992).
The present study examined 44 Chinese HCC cases for muta-
tions in the p53 gene. The result revealed that mutations at
codon 249, a previously identified mutational hotspot, were
exceedingly rare in HCCs from Chinese patients in Sin-
gapore. This finding is in contrast to those from other high
HCC incidence areas, such as certain regions of Africa and
China, where a considerable subset of liver tumours harbour
mutations at this particular codon (Bressac et al., 1991; Hsu
et al., 1991). The hypothesis that p53 mutations at codon 249
could be attributed to AFB1 exposure is supported by the
finding that more than 50% of HCCs from high aflatoxin
exposure areas contain this mutation (Bressac et al.. 1991:
Hsu et al., 1991; Scorsone et al., 1992; Coursaget et al.. 1993;
Li et al., 1993). In contrast, less than 5% of HCCs from low
AFBI exposure areas exhibit mutations at codon 249
(Challen et al., 1992; Kress et al., 1992; Debuire et al., 1993;
Nishida et al., 1993). Therefore the lack of codon 249 muta-
tions in our study subjects suggests that AFBI may not be a
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Fire 2 Direct sequencing of DNA fragments containing exon
7. Right: a normal nucleotide sequence CTA coding for Ile-232.
Left: sequence from case no. 7 showing a T+A transversion
which resulted in substitution of Ile-232 by Asn-232. A normal T
band is also present, indicating that the mutation was
heterozygous. Both forward and reverse strands of each DNA
fragment were sequenced in duplicate. A normal control DNA
sample was included in each sequencing experiment.
Table I p53 mutations in liver cancers
Case Sex HBV Exon Codon Base change Mutation type a.a. change
I F + 5 160 ATG->ACG Transition Met-*Thr
2 M + 5 162 ATC->ATG Transversion Ile->Met
41 M + 6 214 CAT+CGT Transition His-*Arg
7 M + 7 232 ATC+AAC Transversion Ile-*Asn
13 M + 7 236 TAC->TAG Transversion Tyr->Stop
5 M + 7 242 TGC+AGC Transversion Cys->Ser
2 M + 7 248 CGG-*CAG Transition Arg->Gln
40 F - 7 248 CGG-*CAG Transition Arg->Gln
42 M + 7 250 CCC->CTC Transition Pro->Leu
24 M + 7 252 CTC+CCC Transition Leu+Pro
14 M + 8 278 CCT+TCT Transition Pro-*Ser
34 M + 8 284 ACA-*ACC Transversion Thr-*Thr
10 F - 8 291 AAG-*AAA Transition Lys+Lys
16 M - 8 303 AGC+AAC Transition Ser->Asn
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Fgure 3 HaeIlI digestion of DNA fragments containing exon 7.
Lane M, HaeIII-digested pX174 DNA as molecular weight
markers; lane 3. PCR blank control; lane 9, uncut control; lane 8,
DNA from Mahlavu cell line, which is homozygous for codon
249 mutation, as positive control. Lanes 1 and 2 and 4-7, DNA
from HCC cases, showing fragments of 89 and 66 bp resulting
from cuts at wild-type codon 249 (see Materials and methods).
significant risk factor in HCCs in Singapore. Other
aetiological factors, such as HBV infection, may contribute
to the high HCC incidence in this area.
Fujimoto et al. (1994) examined HCC cases from Qidong
and Beijing. China; both were endemic areas for HBV, but
with high and low exposure to AFBI respectively. The overall
mutation rates from the two regions were similar: 60% and
56% respectively. However, the prevalence of codon 249
mutations varied drastically: 52% and 0% in HCCs from
Qidong and Beijing respectively. Our results showed that the
mutation rate (29.5%) in HCCs from Singapore was lower
than those in China, but similar to those in Hong Kong and
Taiwan (Sheu et al., 1992; Hosono et al., 1993; Ng et al.,
1994). In addition, HCCs from Chinese patients residing in
Hong Kong and Taiwan showed infrequent codon 249 muta-
tions. Therefore, given the same ethnic group, the p53 muta-
tion rate as well as the frequency ofcodon 249 mutation may
vary considerably according to geographical locations. Such
differences suggest that multiple aetiological factors, depend-
ing on living conditions and lifestyle, are involved in the
development of HCCs.
The majority ofpoint mutations found in the present study
were base transitions (9/14). This pattern has not been
reported in high-incidence regions, although it has been
observed in low-incidence areas such as Europe and North
America (Unsal et al., 1994). As a large portion of base
transitions are considered to arise from spontaneous muta-
tions in mammalian cells (Hollstein et al., 1991), our result
suggests that endogenous factors or spontaneous processes
may contribute to the mutagenesis of p53 in a subset of
HCCs. For example, the frequent base transitions could be
due to spontaneous mutations as a result of a chronic
regeneration process in the liver (Unsal et al., 1994).
Table I p53 mutations and cinicopathological parameters of the
tumours
Number oftumours
Parameter analysed p53 mutation P-value4
Serum HBsAg
Positive 31 10 (32%) 0.41
Negative 13 3 (23%)
Tumour gradeb
I 66 2 (33%) -
II 7 2 (29%)
III 22 7 (32%)
IV 4 1 (25%)
Tumour sizeb
<5cm 12 2 (17%) 0.19
> 5 cm 27 10 (37%)
Intravascular invasionb
Present 32 12 (38%) 0.05
Absent 7 0 (0%)
'By Fisher's exact test. bResult not available for five cases.
Patients who were seropositive for HBsAg showed a higher
proportion of p53 mutations than those who were negative
(32% vs 23%). Accepting that the quantitative comparison
may not be stable because of the small number of cases, it
nevertheless suggests that HBV viral infection may be
involved to a certain extent in the initiation of p53 muta-
tions. In addition, that mutations occurred more frequently
in larger tumours with intravascular invasions suggests that
p53 mutations are likely to associate with more aggressive
HCCs. This pattern is consistent with studies from low AFBI
exposure regions (Hosono et al., 1993; Nishida et al., 1993),
supporting the hypothesis that, in areas where AFBI does not
play a significant role in tumour initiation, p53 mutations
tend to occur late in HCCs. On the other hand, a recent
report by Aguilar et al. (1994) showed that hotspot muta-
tions at codon 249 were frequent in non-malignant human
liver tissues from high AFB, exposure areas, and suggested
that this specific mutation might be an early event in
hepatocarcinogenesis. Thus, the differential timing of p53
mutations suggests that, while p53 could be mutated by the
potent carcinogen AFB1 in the initiation stage, mutations
may also occur as late events in tumour development under
the influence of other environmental factors or endogenous
processes.
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